Financial Performance - The company expects a net loss attributable to shareholders of the parent company for 2025 to be between -32 million and -47 million yuan, representing a decrease in loss of 63.13% to 74.89% compared to the previous year [2]. - The net loss attributable to shareholders after deducting non-recurring gains and losses is projected to be between -39 million and -58 million yuan, with a reduction in loss of 54.78% to 69.60% year-on-year [2]. - The total profit for the previous year was -150.57 million yuan, with a net profit attributable to shareholders of -127.46 million yuan [3]. Reasons for Losses - The main reasons for the current period's losses include a decline in product sales, price reductions due to centralized procurement policies, and an increase in VAT for self-produced reagent products [4]. Loss Mitigation - The narrowing of losses this year is attributed to a decrease in asset impairment losses and effective cost control measures [4]. Forecast Accuracy - The company has not identified any significant uncertainties affecting the accuracy of this earnings forecast as of the announcement date [5]. - The forecast data is preliminary and the final audited financial data will be disclosed in the official 2025 annual report [6].
之江生物(688317) - 2025 Q4 - 年度业绩预告